Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

PURPOSE Approximately 10% of patients with epidermal growth factor receptor (EGFR)
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …

PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

Purpose: Osimertinib was initially approved for T790M-positive non–small cell lung cancer
(NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However …

ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …

The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …

Background In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth
factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression …

Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …

Background Icotinib has been previously shown to be non-inferior to gefitinib in non-
selected advanced non-small-cell lung cancer patients when given as second-or further-line …